This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

New Use for Glaxo Drug

GlaxoSmithKline (GSK - Get Report) said Tuesday that it received federal approval to sell the drug Avandamet as an initial therapy for diabetes.

Avandamet was approved in 2002 as a second-line therapy for patients who can't control their blood-sugar levels with another drug. The company said it now has an adequate supply of the drug, more than 15 months after federal officials seized batches of Avandamet and the antidepressant Paxil CR and ordered a halt to their sales.

The drugs were confiscated because the Food and Drug Administration said the company had failed to adequately and promptly address manufacturing problems at a plant in Puerto Rico.

In April 2005, GlaxoSmithKline entered an agreement with federal regulators , a month after the products were seized, to improve its manufacturing and quality-control practices.

By the middle of last year, the company was shipping Paxil CR again. Although Avandamet returned to the market 12 months ago , the supply fell well short of demand as quality-control measures were implemented. A spokeswoman said GlaxoSmithKline decided against actively promoting the drug until there was a sufficient supply.

Avandamet combines another GlaxoSmithKline drug, Avandia, with metformin, a now-generic medication. Avandia helps muscle cells be more responsive to insulin, the protein hormone that helps the body convert sugar into fuel. Metformin prompts the liver to produce less sugar. Many diabetics take more than one drug to control their blood-sugar levels, and combination pills offer a measure of convenience.

Avandamet is prescribed for people with Type 2 diabetes, the most common form of the disease, in which the body doesn't produce enough natural insulin or doesn't respond properly to insulin.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,371.89 -306.81 -1.74%
S&P 500 2,033.09 -24.00 -1.17%
NASDAQ 4,699.3810 -72.3820 -1.52%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs